Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

(2016) Xing-Ding Zhang et al.   CANCER CELL

Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs

(2016) Gerard L. Brien et al.   CANCER CELL

DNA methylation in normal and malignant hematopoiesis

(2016) Hamza Celik et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses

(2016) S J de Haart et al.   Blood Cancer Journal

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death

(2015) Yuko Mishima et al.   BRITISH JOURNAL OF HAEMATOLOGY

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

(2015) Eunhee Kim et al.   CANCER CELL

Molecular pathogenesis of multiple myeloma

(2015) Yusuke Furukawa et al.   International Journal of Clinical Oncology

The role for autophagy in cancer

(2015) Eileen White   JOURNAL OF CLINICAL INVESTIGATION

Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma

(2015) Jiro Kikuchi et al.   JOURNAL OF CLINICAL INVESTIGATION

Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow

(2015) T Matthes et al.   LEUKEMIA

KATs in cancer: functions and therapies

(2015) A Farria et al.   ONCOGENE

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

(2015) S Ozaki et al.   Blood Cancer Journal

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

(2015) Ingrid Cifola et al.   Oncotarget

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation

(2015) Aldo M. Roccaro et al.   Cell Reports

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

(2015) Jahangir Abdi et al.   Oncotarget

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

(2014) Sridurga Mithraprabhu et al.   Epigenetics

Histone target selection within chromatin: an exemplary case of teamwork

(2014) M.-E. Lalonde et al.   GENES & DEVELOPMENT

Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells

(2014) Jiro Kikuchi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Epigenetics of hematopoietic stem cell aging and disease

(2014) Motohiko Oshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

(2014) Goro Sashida et al.   Nature Communications

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Regulation and Role of EZH2 in Cancer

(2014) Hirohito Yamaguchi et al.   Cancer Research and Treatment

Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation

(2014) Relja Popovic et al.   PLoS Genetics

Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells

(2013) Piyanuch Sripayap et al.   ACTA HAEMATOLOGICA

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

(2013) Teresa S. Hawley et al.   AMERICAN JOURNAL OF HEMATOLOGY

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

(2013) B. Paiva et al.   BLOOD

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas

(2013) Sebastian Bender et al.   CANCER CELL

NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

(2013) Wen Zhou et al.   CANCER CELL

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells

(2013) Eunhee Kim et al.   CANCER CELL

NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

(2013) Z. Huang et al.   CANCER RESEARCH

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma

(2013) Rogier M. Reijmers et al.   FEBS Journal

Multiple myeloma-initiating cells

(2013) Naoki Hosen   INTERNATIONAL JOURNAL OF HEMATOLOGY

Molecular pathogenesis of multiple myeloma: basic and clinical updates

(2013) Marta Chesi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activityin Vitroandin Vivoby Down-regulating the Expression of Class I Histone Deacetylases

(2013) Jiro Kikuchi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone deacetylase 6–mediated selective autophagy regulates COPD-associated cilia dysfunction

(2013) Hilaire C. Lam et al.   JOURNAL OF CLINICAL INVESTIGATION

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

(2013) Tomoya Muto et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

(2013) Rami Rahal et al.   NATURE MEDICINE

Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer

(2013) Christoph Plass et al.   NATURE REVIEWS GENETICS

Transcriptional regulation by Polycomb group proteins

(2013) Luciano Di Croce et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Determinants of nucleosome positioning

(2013) Kevin Struhl et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells

(2013) Miho Nara et al.   PLoS One

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

(2013) D Chiron et al.   Blood Cancer Journal

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

(2012) A. Chaidos et al.   BLOOD

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma

(2012) B. A. Walker et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Enhancers: emerging roles in cell fate specification

(2012) Chin-Tong Ong et al.   EMBO REPORTS

Discovering common combinatorial histone modification patterns in the human genome

(2012) Changgui Linghu et al.   GENE

A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia

(2012) C. Simon et al.   GENES & DEVELOPMENT

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

(2012) N Hosen et al.   LEUKEMIA

Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF- B Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward Loop

(2012) P. Yang et al.   MOLECULAR AND CELLULAR BIOLOGY

Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact

(2012) Joshua C. Black et al.   MOLECULAR CELL

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

(2012) Panagiotis Ntziachristos et al.   NATURE MEDICINE

Histone methylation: a dynamic mark in health, disease and inheritance

(2012) Eric L. Greer et al.   NATURE REVIEWS GENETICS

Integrin  7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

(2011) P. Neri et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

The diverse functions of Dot1 and H3K79 methylation

(2011) A. T. Nguyen et al.   GENES & DEVELOPMENT

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

(2011) Masahiro Abe   INTERNATIONAL JOURNAL OF HEMATOLOGY

NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming

(2011) Alex J. Kuo et al.   MOLECULAR CELL

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

(2011) Huadong Pei et al.   NATURE

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Classical and/or alternative NF- B pathway activation in multiple myeloma

(2010) Y. N. Demchenko et al.   BLOOD

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells

(2010) E. Martinez-Garcia et al.   BLOOD

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases

(2010) Viviana Moresi et al.   CELL

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Discovery and characterization of chromatin states for systematic annotation of the human genome

(2010) Jason Ernst et al.   NATURE BIOTECHNOLOGY

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

 1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

(2009) K. H. Shain et al.   CANCER RESEARCH

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma

(2008) J. Kirshner et al.   BLOOD

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

(2008) S. Sander et al.   BLOOD

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

(2008) M. B. Meads et al.   CLINICAL CANCER RESEARCH

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells

(2008) J. L.R. Brito et al.   HAEMATOLOGICA

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

(2008) F. Pichiorri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

(2007) J. Marango et al.   BLOOD